This article is more than 5 years old. Information may no longer be current.
Trial set to examine canagliflozin impact on diabetic nephropathy
Click Here to Manage Email Alerts
Researchers have announced they will begin a new study of the sodium glucose co-transporter 2, canagliflozin, to evaluate its role in diabetic nephropathy, according to a manufacturer press release.
The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) is a phase 3 study expected to enroll more than 3,700 patients with type 2 diabetes and diabetic nephropathy, according to the release. The study will examine whether canagliflozin (Invokana, Janssen) will slow the progression of diabetic nephropathy.
“Nearly one-third of all patients with type 2 diabetes will develop evidence of nephropathy. Despite the availability of existing therapies proven to slow its progression, diabetic nephropathy is associated with a 36% mortality rate over a 5-year period,” Norman Rosenthal, MD, FACE, FACP, of Janssen, said in a press release. “Clearly, patients need new, safe and effective treatment options. We look forward to determining if canagliflozin can be used to treat diabetic nephropathy, as we continue to assess additional uses for canagliflozin.”
Primary endpoints will include doubling serum creatinine, end-stage renal failure and cardiovascular death.
For more information:
ClinicalTrials.gov identifier: NCT02065791.